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Simple Summary: Proliferative verrucous leukoplakia is considered by the WHO as an oral poten-
tially malignant disorder that presents the highest tendency to recurrence and malignant transforma-
tion rate. However, to date limited evidence-based prognostic data for oral carcinomas developed
in patients with proliferative verrucous leukoplakia (PVL-OC) have been published, and these car-
cinomas probably perform better than conventional oral carcinomas. In this study we present a
systematic review and meta-analysis to evaluate the current evidence in relation to the prognosis of
oral carcinomas developed in patients PVL-OC.
Abstract: Proliferative verrucous leukoplakia (PVL) is contemplated by the World Health Organiza-
tion (WHO) as an oral potentially malignant disorder (OPMD) with a high the highest malignant
transformation ratio among all OPMD (approximately 50%). Our aim was to evaluate the current
evidence in relation to the prognosis of oral carcinoma developed in patients with proliferative
verrucous leukoplakia (PVL-OC). We searched PubMed, Embase, Web of Science and Scopus for
published studies (upper date limit = June 2021). We evaluated the quality of studies (QUIPS tool).
We carried out meta-analyses, examined inter-study heterogeneity through subgroup and meta-
regression analyses, and performed sensitivity and small-study effects analyses to test the stability
and reliability of results. 23 studies met inclusion criteria (505 patients with PVL, of which 288
developed a total of 504 carcinomas). The meta-analyzed overall mortality rate was 21.29% (pooled
proportions [PP] = 95% confidence intervals [CI] = 8.77–36.36) for PVL-OC, clearly lower than the
34.7–50% mortality rate for conventional oral cancer reported in previous studies. In comparison with
a single study reporting on conventional oral cancers, mortality was significantly lower for PVL-OC
(hazard ratio = 0.29 [95%CI = 0.10–0.89], p = 0.03). Univariable meta-regression verified that case
series that presented higher proportions of verrucous carcinomas showed a better survival of PVL-OC
(p = 0.05), but not with higher proportion of oral squamous cell carcinomas (p = 0.74). Significant
differences were not found for other relevant variables such as follow up period (p = 0.44) or multi-
ple tumor development (p = 0.74). In conclusion, PVL-OC show favorable prognostic parameters,
especially with regard to the mortality rate.
Keywords: malignant transformation; meta-analysis; oral cancer; prognosis; proliferative verrucous
leukoplakia; systematic review
1. Introduction
An international seminar convened by the World Health Organization (WHO) Col-
laborating Center for Oral Cancer in Glasgow (Scotland) in 2020 has reported an update
Cancers 2021, 13, 4843. https://doi.org/10.3390/cancers13194843 https://www.mdpi.com/journal/cancers
Cancers 2021, 13, 4843 2 of 16
on nomenclature and classification of oral potentially malignant disorders (OPMD) [1].
Proliferative verrucous leukoplakia (PVL) has been defined by this expert group as a
distinct form of multifocal oral leukoplakia characterized by having a progressive clini-
cal course, changing clinical, and histopathological features, associated with the highest
malignant transformation rate in comparison with other OPMDs. Some members of our
research group who participated as experts in the aforementioned consensus meeting,
were commissioned to update the information related to the malignant transformation of
PVL, which they performed through a systematic review and meta-analysis that reported
a rate of malignancy of 43.87% (95%CI = 31.93–56.13) [2], slightly lower than previously
published by Iocca et al. (49.5% (CI 26.7–72.4%) [3]. A pertinent fact of our study refers to
the wide variability in the proportion of PVL with oral cavity cancer development across
the studies assessed in our meta-analysis, ranging between 0 and 100% [4,5] and between
14.29 and 75% [6,7] after the omission of extreme values.
One of the groups that has studied this aspect in greater depth has reported that in its
series of 55 patients with PVL, 27 patients developed oral cancer of which 11 patients devel-
oped multiple tumors (40.74%) [8]. One might think that PVL, because it is an OPMD with
a high rate of malignancy, due to it has a notable tendency to multiple tumor development,
in most cases, resistant to all forms of treatment, would lead to the development of carci-
nomas of poor prognostic evolution. However, to date limited evidence-based prognostic
data for oral carcinomas developed in patients with proliferative verrucous leukoplakia
(PVL-OC) have been published and one series that analyze prognostic parameters indicate
that these carcinomas probably perform better than conventional oral carcinomas [9], with
a 5-year mortality rate ranging from 34.70% to 50% [10,11]).
Based on this background, it seems pertinent to evaluate current evidence in relation
to the prognosis of PVL-OC, to determine the mortality rate of PVL-OC and to explore
the impact of potential covariables on survival (i.e., follow up periods, multiple tumor
development, and histology of carcinomas).
2. Materials and Methods
Our study was designed complying with high standards criteria developed by Cochrane
Handbook for Systematic Reviews of Interventions [12], Cochrane Prognosis Methods
Group [13] and Centre for Reviews and Dissemination (CRD)’s guidance for undertak-
ing reviews in health care [14]. MOOSE and PRISMA reporting guidelines were closely
followed [15,16].
2.1. Protocol
A protocol was a priori designed describing the planned methods of the study, in order
to improve the precision and transparency, and to minimize the risk of bias. This study
protocol was registered in PROSPERO international prospective register of systematic
reviews (www.crd.york.ac.uk/PROSPERO; CRD42021267896 code was assigned) [17]. The
protocol also followed PRISMA-P statement [18].
2.2. Search Strategy
We searched MEDLINE (accessed through PubMed), Embase, Web of Science and Sco-
pus databases for studies published before June-2021, without lower date limits restriction.
Search strategy was designed to maximize sensitivity and performed by combining the fol-
lowing keywords: “proliferative” AND “verrucous” AND “leukoplakia”. Due to the lack
of specific thesaurus terms for proliferative verrucous leukoplakia, Emtree and/or MeSH
terms were not applied. Reference lists of retrieved studies were also manually searched
for additional relevant studies. All references were handled and duplicates eliminated
using the software Mendeley v.1.19.8 (Elsevier, Amsterdam, The Netherlands).
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2.3. Eligibility Criteria
Inclusion criteria: (1) Original primary-level studies published in any language or pub-
lication date; (2) Report of mortality and/or clinicopathological parameters of the patients
with PVL-OC; (3) For results derived from the same study population, we included the
most informative studies; if overlapping populations were suspected, the name of authors,
affiliations, treatment centers, and recruitment periods were checked and compared.
Exclusion criteria: (1) Retractions, case reports, reviews, meta-analyses, letters, edito-
rials, personal opinions, comments, meeting abstracts, and book chapters; (2) Preclinical
research (animal experimentation and/or in vitro studies); (3) Lack of clinicopathological
parameters or survival data; (4) Insufficient data for statistical analysis; (5) Carcinomas
developed in anatomical sites other than the oral cavity; (6) overlapping populations (see
inclusion criterion No. 3).
2.4. Study Selection Process
The eligibility criteria were applied independently by two authors (M.Á.G.-M. and
P.R.-G.) in two phases: First, titles and abstracts were screened searching for articles
apparently meeting our inclusion criteria; Second, papers were full-text read and excluding
the articles not meeting our eligibility criteria. Discrepancies between authors were resolved
by consensus. An authors’ agreement score was calculated using Cohen’s kappa (κ)
statistic [19], obtaining an almost perfect score (99.20% of agreement, κ = 0.93).
2.5. Data Extraction
Two authors (M.Á.G.-M. and P.R.-G.) independently extracted data—filling out a
standardized data collection form in Word and Excel (v.16/2018, Microsoft. Redmond,
WA)—from the selected articles. Data expressed as order statistics (i.e., medians, interquar-
tile, and/or minimum-maximum ranges) were computed and transformed into means ±
standard deviations (SD) using the methods proposed by Luo et al. (2018) and Wan et al.
(2014) [20,21]. Means ± SDs from two or more different subgroups were combined into
a single dataset if necessary, applying the Cochrane Handbook’s formula [12]. Data was
collected on the first author and publication year, country and continent, follow up and
recruitment periods, design of study, sample size of PVL-OC, presence of tumor multiple
development and number of tumors, tumor subsites, age and sex of patients, tobacco
consumption, mortality data of patients, and clinicopathological parameters (histology
of carcinomas, differentiation grade of squamous cell carcinomas, clinical stage, T status
and/or N status). In one study [22], the prognostic value of the PVL-OC was compared
with that of the conventional OC. From these selected studies we attempted to extract
data on the outcome overall survival (defined as the time elapsed from date of diagno-
sis/surgery to date of death by any cause). Disease-free survival or other recurrence
parameters were not reported.
2.6. Evaluation of Quality and Risk of Bias
Risk of bias (RoB) was assessed in primary-level studies using the Quality in Prognosis
Studies-QUIPS tool, supported by Cochrane Prognosis Methods Group for prognosis stud-
ies [23]. QUIPS considers the following domains: (1) Study participation, (2) Study attrition,
(3) Prognostic Factor Measurement, (4) Outcome Measurement, (5) Study confounding,
and (6) Statistical Analysis and Reporting [24]. RoB was qualified as low, moderate, or high
for each domain. RoB was assessed by two authors (M.A.G.M. and P.R.G.). Discrepancies
between authors were resolved by consensus.
2.7. Statistical Analysis
Proportions from primary-level studies—expressed as percentages—were calculated
by extracting raw numerators (number of patients with PVL-OC and positive parame-
ters, i.e., number of deaths, patients with verrucous or squamous cell carcinomas, well-
differentiated squamous cell carcinomas, T1/2, N+, M+ and advanced stage) and denom-
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inators (total number of patients with PVL-OC). Their corresponding 95% confidence
intervals (CIs) were estimated for primary-studies according to the score-test statistic [25].
The influence of studies with extreme proportions values (i.e., 100%, 0% or close) was mini-
mized by using Freeman–Tukey double-arcsine transformation to stabilize the variance of
proportions [26]. The mortality rate and clinicopathological parameters of patients with
PVL-OC were meta-analyzed by combining proportions (pooled proportions, PP) and 95%
CIs using the inverse-variance method under a random-effects model (based on the Der
Simonian and Laird method). Forest plots were constructed for all meta-analyses.
Heterogeneity between studies was checked using the χ2 based Cochran’s Q test.
Given the low statistical power of this test, p < 0.10 was considered significant. We also
used Higgins I2 statistic to quantify the percentage heterogeneity (considering values of
50–75% as moderate-to-high degree of inconsistency across the studies), which estimates
what proportion of the variance in observed effects reflects variation in true effects, rather
than sampling error [27,28]. Preplanned stratified meta-analyses (by geographical area)
were performed to identify potential sources of heterogeneity for survival parameters.
Furthermore, additional univariable meta-regression analyses, using the restricted maxi-
mum likelihood (REML) method, were conducted to explore the potential effect of study
covariates (follow up period, tumor multiple development, verrucous and oral squamous
cell carcinomas) on the mortality of patients with PVL-OC [29]. Taking into consideration
the low number of observations for meta-regressions, the p-values were recalculated using
a permutation test based on Monte Carlo simulations [30] (10,000 permutations series
were run to obtain enough precision [31]). Weighted bubble plots were also constructed to
graphically represent the fitted meta-regression lines.
Furthermore, the prognostic value of PVL-OC (compared to conventional OC) was
analyzed. Due to only one study [22] reporting data for this analysis, meta-analysis could
not be performed for this parameter. Hazard ratio (HR) with 95% CI was used to estimate
the potential impact of PVL-OC on overall survival. As authors did not explicitly report
HR with 95% CIs, we made an estimation using the methods described in Parmar et al. [32]
and Tierney et al. [33].
Furthermore, secondary analyses were carried out to test the stability and reliability
of our meta-analytical results. Therefore, sensitivity analysis series were carried out to
investigate the influence of each primary-level study on the pooled estimates [34], repeating
sequentially the meta-analyses, omitting one study at a time (“leave-one-out” method).
Finally, small-study effects and potential biases, such as publication bias, were evaluated
constructing funnel plots and using the Egger [35] regression test (performing a linear
regression of the effect estimates on their standard errors, weighting by 1/[variance of
the effect estimate], considering a pEgger-value < 0.10 as significant). As the absence of
small-study effects was confirmed, as advised, additional analyses (e.g., non-parametric
Trim & Fill method) were not used to avoid type-I errors (i.e., false-positives missing
studies) and subsequent misleading funnel plot asymmetry corrections [36]. Stata software
was used for statistical analysis (v.16.1, Stata Corp, College Station, TX, USA).
3. Results
3.1. Results of the Literature Search
A total of 827 records were identified during the identification and selection process
(Figure 1 Flow diagram): 262 from the Web of Science, 204 from Embase, 193 from Scopus,
169 from PubMed, and one after handsearching the reference lists of retrieved studies. After
eliminating duplicates, 375 studies were considered potentially eligible. Then, their titles
and abstracts were screened and 45 papers selected for full-text reading (22 of them did
not meet our eligibility criteria and were excluded; their references and exclusion reasons
are listed in the Supplementary Materials, pp. 32–34). Finally, 23 studies were included in
the systematic review’s final sample—23 for qualitative evaluation and 21 for quantitative
meta-analysis- [5–7,22,37–55].
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Figure 1. The flow diagram depicts identification and selection process of studies addressing the behavior PVL-OC.
3.2. Study Characteristics
Table 1 summarizes the main characteristics of the selected studies, and Table S1
summarizes in more detail the characteristics of each primary-level study (Supplementary
Materials, pp. 3–5). Twenty-three studies published between 1985 and 2021 recruited
543 patients with PVL, of which 288 patients developed a total of 504 oral carcinomas. Nine
studies were conducted in Europe (3 in Italy, 3 in Spain, 2 in UK and 1 in France), 9 in
North America (all in USA), 3 in Asia (1 each in India, Israel and Malaysia), 1 in South
America (Brazil), and 1 was a multicontinent multicentric study (Brazil, USA).
Table 2 exhibits the results of the conducted meta-analyses in the present study. It was
feasible to perform meta-analysis for the mortality rate of patients with PVL-OC (183 pa-
tients with PVL that developed cancer, enrolled in 14 studies), the proportion of patients
with verrucous carcinomas and oral squamous cell carcinomas (255 patients/20 studies, re-
spectively), with well-differentiated oral squamous cell carcinomas (49 patients/8 studies),
with a tumor size of T1/2 (13 patients/2 studies), with N+ status (19 patients/3 studies),
with M+ status (13 patients; 2 studies), and I/II-clinical stage (46 patients; 3 studies). In
addition, the prognosis of these patients (with PVL-OC) was estimated for the overall sur-
vival parameter, in comparison to a control group of patients who developed conventional
oral carcinomas (without prior history of proliferative verrucous leukoplakia) (60 patients;
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one study [22]). Finally, several meta-regression analyses were carried out to estimate the
potential impact of different variables (i.e., follow up period, tumor multiple development,
verrucous and oral squamous cell carcinomas) on the mortality of patients with PVL-OC.
Table 1. Summarized characteristics of reviewed studies.
Total 23 Studies
Year of publication 1985–2021
Number of patients
PVL 543
Developing oral cancer 288
Number of tumors 504
Sample size, range
PVL 3–81
Developing oral cancer 1–48
Number of tumors 1–130
Study design
Retrospective longitudinal 23 studies
Prospective longitudinal 1 studies
Follow up periods
Mean of means 65.63 months
Range 14–174
Geographical region
Europe 9 studies, 4 countries: France, Italy, Spain, UK
North America 9 studies, 1 country: USA
Asia 3 studies, 3 countries: India, Israel, Malaysia
South America 1 study, 1 country: Brazil
Multicontinent 1 study, 2 countries: Brazil-USA
Total 4 continents (9 countries)
Table S1 (Supplementary Materials, pp. 3–5) exhibits in more detail the characteristics of each study.
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Abbreviations: Stat., statistical; Wt, method of weighting; ES, effect size estimation; PP, pooled proportion; HR, hazard ratio; CI, confidence
intervals; REM, random-effects model; D-L, DerSimonian and Laird method, PVL, proliferative verrucous leukoplakia; OC, oral carcinoma,
PVL-OC, oral carcinomas arising in patients with pre-existing proliferative verrucous leukoplakia; SCC, squamous cell carcinoma. a—More
information in the supple, b—Proportion meta-analysis, c—Proportion meta-analyses (Subgroup analyses), d—Prognosis meta-analysis,
e—Effect of study covariates on the mortality rate among patients with PVL-OC. A meta-regression coefficient >0 indicates a greater impact
of covariates on the mortality rate. f—p-value ± standard error recalculated after 10,000 permutations based on Montecarlo simulations,
g—Proportion of between-study variance explained (adjusted R2 statistic) using the residual maximum likelihood (REML) method. A
negative number for proportion of heterogeneity explained reflects no heterogeneity explained.
3.3. Qualitative Evaluation
The quality plot (Figure 2) depicts the RoB analysis conducted using the QUIPS tool.
Potential sources of bias were classified and summarized across the following six domains:
Study participation. RoB was low in 34.78% of reviewed studies, moderate in 56.52%,
and high in 8.70% (Figure 2). Most frequent biases were related to the lack of an adequate
description of the characteristics of the sample of patients with PVL that developed oral
carcinomas. In general, all studies reported the origin of the patients, and although the
PVL and cancer samples were small, this is a logical aspect and difficult to resolve given
the low prevalence of PVL.
Study attrition. RoB was moderate in 91.30% of the reviewed studies and high in
8.70% (Figure 2). The lack of reporting essential information on the follow-up period
was a frequent potential source of bias. No study reported the dropout rate during the
follow-up period and/or the attempt to collect information from lost patients, reasons for
follow-up drop out, or the description of the characteristics of lost patients and/or those
who completed the full follow-up period. This information is essential to ensure that the
final sample adequately represents the baseline sample reported in primary-level studies.
Prognostic factor measurement. RoB was low in 56.52% of the reviewed studies, moderate
in 34.78%, and high in 8.70% (Figure 2). The most relevant potential bias found was the
failure to report the criteria used in primary-level studies for PVL diagnosis or the use
of non-exhaustive clinical or histopathological criteria elaborated under consensus or
endorsed by scientific publications.
Outcome measurement. RoB was low in 13.04% of reviewed studies and moderate in
86.96% (Figure 2). Mainly due to the diagnosis of oral cancer is universal and very probably
not biased, the most frequent bias found was the failure to report the clinicopathological
characteristics with prognostic value of these patients and their carcinomas (T status, N, M,
clinical stage, etc.).
Study confounding. RoB was low in 43.48% of reviewed studies, moderate in 39.13%,
and high in 17.39% of the reviewed studies (Figure 2). The most frequent biases found
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were not taking into account in the study design potentially confounding factors (e.g., age,
smoking, alcohol consumption) or the failure to measure them.
Figure 2. Quality plot graphically representing the risk of bias (RoB) analysis. The most relevant
sources of bias were assessed in primary-level studies using the Quality in Prognosis Studies tool
(QUIPS) -developed by Cochrane Prognosis Methods Group- across the following six domains:
(D1) Study participation, (D2) Study attrition, (D3) Prognostic Factor Measurement, (D4) Outcome
Measurement, (D5) Study confounding, and (D6) Statistical Analysis and Reporting. RoB was scored
as low RoB (depicted in green colour), moderate RoB (yellow), or high RoB (red) for each domain.
Statistical analysis and reporting. RoB was moderate in 4.35% of reviewed studies and
high in 96.65% (Figure 2). The most frequent and relevant source of potential bias was the
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lack of use a control group in the study design (i.e., the comparison of mortality rates in
patients who developed conventional oral carcinomas without prior history of proliferative
verrucous leukoplakia). A single study presented a control group but did not report hazard
ratios with 95% confidence intervals, essential to assess the direction, precision, and effect
size of time-to-event variables (e.g., disease-free survival or overall survival).
3.4. Quantitative Evaluation (Meta-Analysis)
3.4.1. Quantitative Evaluation of Survival Parameters of Patients with PVL-OC
Meta-analysis on mortality rate of patients with PVL-OC. A random-effects model esti-
mated a mortality pooled proportion (PP) of 21.29% (95%CI = 8.77–36.36) in patients with
PVL-OC. There was a significant moderate degree of inter-study heterogeneity (p < 0.001,
I2 = 65.49%; Figure 3, Table 2).
Figure 3. Forest plot graphically representing the meta-analysis of the mortality rate in PVL-OC. Random-effects model,
DerSimonian, and Laird method. Pooled proportions (expressed as percentage) were used as effect size measure (expressed
in bold). PP, pooled proportions; CI, confidence intervals; PVL-OC, oral carcinomas developed in patients with proliferative
verrucous leukoplakia.
Subgroup meta-analysis. The meta-analysis stratified by geographical area did not show
a significant variability of the mortality rate among continents (p = 0.06; Table 2, Figure S1,
Supplementary Materials p. 6). Europe and North America maintained a mortality rate
close to the overall rate (Europe: PP = 30.46%, [95%CI = 10.90–53.57]; North America:
PP = 27.40% [95%CI = 6.57–53.27]), while Asia and South America obtained a much lower
rate, although based on a lower sample size with imprecise and wider confidence intervals
(Asia: PP = 2.78% [95%CI = 0.00–18.97]: South America: PP = 0.00% [95%CI = 0.00–48.99]).
Meta-regression analysis. Univariable meta-regression analyses (Table 2; Figures S2–S5,
Supplementary Materials, pp. 7–10) revealed a significant lower mortality rate in patients
with PVL-OC that developed verrucous carcinomas (p = 0.05). After performing the
residual maximum likelihood (REML) method we confirmed the relevance of this variable
explaining the proportion of between-study variance (adjusted R2 = 100%), being the
most important explanatory source of heterogeneity for mortality rate in the present study.
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Mortality rates did not vary significantly for the rest of the potential covariates investigated
(influence of follow up period [p = 0.44], tumor multiple development [p = 0.74], and
conventional oral squamous cell carcinomas [p = 0.74]).
Overall survival of PVL-OC (vs. conventional OSCC). This meta-analysis could not be
conducted, because only one study published sufficient data for its inclusion (i.e., presence
of control group). In this study, Akrish et al. [12] reported a significantly better overall
survival for patients with PVL-OC in comparison with patients with oral cancer without
prior PVL (HR = 0.29 [95%CI = 0.10–0.89], p = 0.03; Table 2).
3.4.2. Quantitative Evaluation of Clinicopathological Parameters of Patients with PVL-OC
Meta-analysis on verrucous carcinomas in patients with PVL-OC. A random-effects model
estimated that patients with PVL frequently develop verrucous carcinomas (PP = 33.66%
[95%CI = 17.58–51.43]). There was a significant high degree of inter-study heterogeneity
(p < 0.001, I2 = 81.72%; Table 2, Figure S6, Supplementary Materials, p. 11).
Meta-analysis on oral squamous cell carcinomas in patients with PVL-OC. A random-effects
model confirmed that patients with PVL mainly develop conventional oral squamous cell
carcinomas (PP = 72.21% [95%CI = 52.95–88.64]). A considerable high degree of hetero-
geneity was found among studies (p < 0.001, I2 = 85.26%; Table 2, Figure S7, Supplementary
Materials, p. 12).
Meta-analysis on well-differentiated oral squamous cell carcinomas in patients with PVL-
OC. A random-effects model also confirmed that these patients mainly develop well-
differentiated oral squamous cell carcinomas (PP = 78.41% [95%CI = 37.24–95–100.00]).
A high degree of heterogeneity was observed (p < 0.001, I2 = 81.55%; Table 2, Figure S8,
Supplementary Materials, p. 13).
Meta-analysis on TNM and clinical stage in patients with PVL-OC. A random-effects model
estimated that these patients mainly develop T1/2 tumors (PP = 99.93% [95%CI = 81.37–100.0],
with N- status (N+: PP = 0.60% [95%CI = 0.00–15.86]), M- status (M+: PP = 0.07% [95%CI =
0.00–18.63]), and present an early (I/II) clinical stage (PP = 89.88% [95%CI = 59.21–100.0]).
Nevertheless, these meta-analyses were conducted over low sample sizes (n = 2 to 3 stud-
ies), showing imprecision (i.e., wide confidence intervals) and therefore, a low quality of
evidence (Table 2, Figures S9–S12, Supplementary Materials, pp. 14–17).
3.5. Quantitative Evaluation (Secondary Analyses)
3.5.1. Sensitivity Analysis
Substantial variations were not found in the overall results after the sequential repe-
tition of meta-analyses across the sensitivity analysis series omitting one study at a time
(“leave one-out” method; Tables S2–S9, Supplementary Materials, pp. 18–25). According to
this secondary analysis the results of our meta-analyses do not depend on the influence of
a particular individual primary-level study, reaffirming the stability of our results.
3.5.2. Analysis of Small-Study Effects
Visual inspection analysis of funnel plots’ asymmetry and the Egger’s regression
tests confirmed the absence of small-study effects for all parameters under investigation
(mortality rate: pEgger = 0.65; verrucous carcinomas: pEgger = 0.77; oral squamous cell
carcinomas: pEgge r = 0.44; well-differentiated squamous cell carcinomas: pEgger = 0.87; N
status: pEgger = 0.90; clinical stage: pEgger = 0.87; T and M status: not applied [n = 2 studies,
respectively]; Figure S13–S18, Supplementary Materials, pp. 26–31); therefore, biases such
as publication bias could be potentially ruled out, reaffirming the reliability of our results.
4. Discussion
Our current systematic review carried out on a total of 23 studies and 543 patients
with PVL indicates that 288 patients developed 504 oral carcinomas. Today it is accepted
that PVL is the OPMD that presents the highest malignant transformation rate, close
to 50% of cases [2,3] jointly with a high probability of multiple tumors development
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behaving as a field of cancerization [8,9,56,57]. Different therapeutic approaches have
been reported for the management of PVL, including conventional surgery, CO2 laser
therapy, or even pharmacological treatment, although none of them have been satisfactory
and so this OPMD has also been shown to be resistant to any form of treatment with
frequent recurrence of lesions on which new carcinomas may appear [1,58,59]. Despite
all this, there is limited knowledge about the prognosis of carcinomas developed on PVL.
Hypothetically, in a condition such as PVL, with a very high rate of malignancy and a
notable tendency to the development of multiple tumors, the prognosis of carcinomas
that appear during its evolution should be poor. However, our meta-analytical results
demonstrate otherwise. In our study we have found an overall mortality of 21.29% for
PVL-OC. Although the published series, with the exception of one paper [22], do not
offer data relative to a control group, this mortality seems considerably lower than the
mortality of conventional carcinoma not developed from PVL, published in previous
official reports such as the SEER program (Surveillance, Epidemiology, and End Results
Program-SEER [10]. This program provides information on cancer statistics among the U.S.)
that reported a mortality of 34.70%, as well as in other seminal papers [11] that indicate a
mortality close to 50%; in the Akrish et al. series [22], the only group that uses a control
group for conventional cancers, a probability of death from PVL-OC is significantly lower
(p = 0.03) than the probability of death from a conventional carcinoma. The reason for
justifying this low mortality is currently unknown. There are not enough studies that offer
data on the TNM parameters and PVL-OC stage, so we cannot provide any information in
this regard. However, in relation to the influence of the PVL-OC lineage, some interesting
considerations should be made. Our meta-analysis shows that 33.66% of the patients
developed verrucous carcinomas while 72.21% developed OSCCs. Likewise, we verified
that those series that presented higher proportions of verrucous carcinomas showed a
better patient survival (p = 0.05), which is absolutely logical if we take into account that
verrucous carcinoma exclusively develop local malignancy with no tendency to metastasis;
on the contrary, in those series that presented higher proportions of OSCCs, mortality did
not worsen (p = 0.74), which indicates in our view that PVLs generate OSCC in themselves
with a good prognosis. Our group has recently reported that OSCCs developed on oral
lichen planus (OLP) also present a good prognosis with low mortality rates (15.48%) [60],
which we attribute to the fact that cancers developed on OLP themselves have a better
behavior related with their smaller size, less tendency to generate metastasis, early stage,
and good differentiation. Although there are insufficient data to extrapolate these results
to PVL-OC, series reporting the degree of PVL-OC differentiation (8 studies, 49 cancer
patients) indicate a majority belong to well-differentiated carcinomas (78.41%).
Our results regarding multiple tumor development in PVL are also of interest. It
could be expected that the development of multiple tumors in PVL could lead to higher
patient’s mortality. However, this is not the case in our meta-analysis, mortality was not
affected by PVL giving rise to multiple tumors (p = 0.74). This observation has also been
made and reported by our research group in patients who develop multiple carcinomas
in OLP [60]. We think that the development of multiple tumors in OLP will not affect
survival if all of them display very good prognostic parameters, and perhaps the same
interpretation could be given for the multiple tumors that develop in PVL, although this is
a hypothesis that should be tested. Another comment of interest concerns the influence
of follow-up on mortality in the series. It could be hypothesized that, since PVL has
a high malignant rate among OPMDs, with a high frequency of multiple tumors, and
recurrent after treatment, long prolonged follow-up periods should be accompanied by
higher mortality rates. However, this was not the case in our meta-analysis, the follow-up
did not affect the survival of the series (p = 0.44), which is probably also indicating the
good behavior of PVL-OC related on characteristics inherent to their own biopathology.
We also should point out that the studies included in this systematic review and
meta-analysis have not been conducted with the same rigor, most of them presenting a
high potential risk of bias. Based on our qualitative analysis, we recommend that (1) future
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studies investigating the behavior of oral carcinomas in PVL patients report in greater
detail the demographic characteristics of patients with cancer development; (2) the follow-
up periods must be long and well communicated; this is essential in prognostic studies,
where it must be guaranteed a minimum period of time that allows the appearance of the
investigated event (i.e., oral cancer development); (3) studies should diagnose patients with
PVL based on exhaustive diagnostic criteria, preferably evidence-based (e.g., Gonzalez-
Moles et al. 2021 [59]); (4) the diagnosis of cancer is universal and reliable in studies, but
the clinicopathological characteristics of patients with PVL who develop cancer should be
communicated in greater detail (e.g., T/N/M-status, clinical stage, etc.); (5) the analysis of
potentially confounding factors (e.g., sex, age, tobacco consumption) is the Achilles heel of
observational studies, a correct design, analysis, and reporting is imperative taking these
factors into account; (6) only one study presented a control group and probably some of
the included studies constitute sources of indirect evidence (i.e., studies not conducted or
designed with the same aim of comparing the prognostic value of PVL vs. conventional
carcinomas), which decreases the quality of the evidence. Therefore, a careful study design
adopting an appropriate control group is essential to achieve the goals of future research
papers investigating the behavior of carcinomas that develop in patients with PVL.
Our study also presents some potential limitations that should also be discussed. First,
a considerable degree of inter-study heterogeneity was observed, a frequent finding in
meta-analyses of proportions [61]. Consequently, random-effects models were carried
out in all meta-analyses to account for heterogeneity. In addition, we performed random-
effects meta-regression analyses performing the residual maximum likelihood (REML) to
produce an adjusted R2 statistic, which estimates the proportion of the inter-study variance
explained by covariates; important explanatory sources of heterogeneity were found after
the application of this method (e.g., the impact and variability on mortality rates in patients
with PVL which developed verrucous carcinomas and oral squamous cell carcinomas).
Second, the sample sizes of the primary-level studies were very small (i.e., low number of
cancers per study). However, due to the low prevalence of PVL, this limitation represents a
difficult challenge to overcome. Future multicenter cohort studies should be developed
to obtain more precise results, with narrower confidence intervals, providing a higher
quality of evidence. Finally, an inherent limitation of the included primary-level studies
-in our methodological reflections on RoB- was the failure to report relevant information
and parameters, limiting the number of observations in secondary analyses (e.g., tobacco
consumption or alcohol drinking). Given the methodological and clinical relevance of these
variables, future studies should publish their datasets in a more rigorous way, preferably
reporting individual patient data. Despite the above limitations, our systematic review and
meta-analysis is innovative—showing for the first time more precise and evidence-based
results, derived from-208 PVL-OC which developed 504 oral carcinomas—robust, and
reliable; it is also supported by our sensitivity analyses and funnel plots and provides
recommendations for the design of future studies on this topic.
5. Conclusions
In conclusion, our systematic review and meta-analysis presents consistent results and
evidence that PVL-OC show a favorable prognostic behavior hypothetically related to char-
acteristics inherent to the tumor’s own biopathology. Future studies on this topic should
report prognostic clinical–pathological data for these carcinomas in order to elucidate the
reasons for this statement.
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